



International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE

KETOGENIC DIET IN THE TREATMENT OF EPILEPSY IN
CHILDREN: A COMPREHENSIVE REVIEW

DOI

[https://doi.org/10.31435/ijitss.2\(50\).2026.5509](https://doi.org/10.31435/ijitss.2(50).2026.5509)

RECEIVED

06 March 2026

ACCEPTED

15 June 2026

PUBLISHED

30 June 2026

LICENSE



The article is licensed under a **Creative Commons Attribution 4.0 International License**.

© The author(s) 2026.

This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

KETOGENIC DIET IN THE TREATMENT OF EPILEPSY IN CHILDREN: A COMPREHENSIVE REVIEW

Magdalena Maroszek (Corresponding Author, Email: m.maroszek13@gmail.com)

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0005-3826-1788

Małgorzata Anna Ziólek

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0006-4162-7899

Kornelia Domagała

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0008-4148-9320

Kamil Szymczak

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0002-7719-7625

Bartosz Janik

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0003-2112-1477

Ariadna Bakier

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0008-3812-5403

Filip Gałązka

Copernicus PL Sp. z o.o., St. Adalbert Hospital, aleja Jana Pawła II 50, 80-462 Gdańsk, Poland

ORCID ID: 0009-0008-1301-7326

Albert Wiatr

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0009-0001-3871-5787

Agata Olecka

7th Naval Hospital in Gdańsk, Gdańsk, Poland

ORCID ID: 0000-0002-2101-9603

Jakub Cegielski

The Provincial Hospital in Bielsko-Biala, Bielsko-Biala, Poland

ORCID ID: 0009-0009-4222-0996

ABSTRACT

Objectives: This review assesses the clinical efficacy of ketogenic diet therapy (KDT) for pediatric drug-resistant epilepsy. We also examine safety profiles and practical protocol implementation.

Methods: Evidence was synthesized from recent randomized controlled trials. We incorporated systematic reviews alongside large-scale meta-analyses to investigate specific KDT variants. The evaluated protocols included the classic ketogenic diet, the modified Atkins diet, and low glycemic index therapy. The target demographic was entirely restricted to patients aged 0 to 18 years who were unresponsive to two or more antiepileptic drugs.

Key findings: The data indicate that roughly half of pediatric patients achieve a seizure frequency reduction of 50% or greater. Children utilizing KDT are over five times more likely to experience this reduction compared to those receiving standard pharmacological care. The classic formulation is the benchmark for infants and patients requiring enteral feeding. Less restrictive variants provide better palatability for older children. They maintain clinically significant efficacy, though median seizure reduction occasionally trends lower than the strict classic diet. Gastrointestinal adverse effects happen frequently during initiation. Vomiting and constipation are typical but easily managed in a clinical setting. Recent data show the diet works as effectively as adding a new antiseizure medication for infants as young as one month.

Conclusion: Ketogenic diet therapy provides a highly potent non-pharmacological treatment for refractory pediatric epilepsy. Long-term adherence requires highly individualized dietary adjustments. Furthermore, clinical success demands rigorous multidisciplinary oversight coupled with extensive family training.

KEYWORDS

Ketogenic Diet, Drug-Resistant Epilepsy, Children, Modified Atkins Diet, Dietetic Management, Antiseizure Medication

CITATION

Magdalena Maroszek, Małgorzata Anna Ziółek, Kornelia Domagała, Kamil Szymczak, Bartosz Janik, Ariadna Bakier, Filip Gałązka, Albert Wiatr, Agata Olecka, Jakub Cegielski. (2026) Ketogenic Diet in the Treatment of Epilepsy in Children: a Comprehensive Review. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5509

COPYRIGHT

© **The author(s) 2026.** This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

1.Introduction

Epilepsy represents one of the most pervasive chronic neurological conditions in the pediatric population. Millions of children worldwide require long-term medical management to control abnormal electrical discharges in the brain. A large proportion of these patients achieve clinical stability through the administration of conventional antiseizure medications. A stubborn subset fails to respond completely. The International League Against Epilepsy defines drug-resistant epilepsy as the failure of adequate trials of two tolerated, appropriately chosen medication schedules to achieve sustained seizure freedom. This precise definition captures a devastating clinical reality. For these children, uncontrolled seizures are a severe threat to neurodevelopment. The developing brain is highly vulnerable to the electrical storms of recurrent seizures. Cognitive maturation stalls. Behavioral regression frequently occurs. Caregivers face immense daily stress managing unpredictable, potentially life-threatening episodes.

When two antiseizure medications fail, the probability of achieving seizure control with a third or fourth drug drops precipitously. The likelihood approaches zero. This statistical reality forces neurologists to look beyond standard pharmacotherapy early in the treatment pathway. Surgical evaluation is one route for patients with focal lesions. Vagus nerve stimulation offers another palliative option. Dietary therapy remains a highly effective, non-surgical intervention for a broad spectrum of seizure types. The ketogenic diet forces a fundamental shift in human energy metabolism. It replaces glucose with fat as the primary source of cellular fuel.

Fasting has been recognized since antiquity for its anticonvulsant properties. Modern medical application began in the 1920s when researchers designed a specific high-fat, low-carbohydrate regimen. This protocol mimicked the biochemical effects of starvation without imposing dangerous caloric deprivation on growing children. The classic ketogenic diet relies on a rigid macronutrient ratio. Typically, this is formulated

at a 3:1 or 4:1 lipid-to-non-lipid ratio. Three to four grams of fat are consumed for every one gram of combined protein and carbohydrates. This severe imbalance forces a systemic metabolic switch. The liver begins oxidizing fatty acids into ketone bodies. Acetoacetate, beta-hydroxybutyrate, and acetone are produced in high quantities. These molecules readily cross the blood-brain barrier. They replace glucose as the primary energetic substrate for the central nervous system.

The exact anticonvulsant mechanism remains a subject of intense academic debate. Several robust hypotheses exist based on decades of neurochemical research. Ketone metabolism alters the fundamental energy dynamics of neurons. It increases the synthesis of gamma-aminobutyric acid, the primary inhibitory neurotransmitter in the mammalian brain. It decreases neuronal excitability by hyperpolarizing cell membranes. Mitochondrial biogenesis is stimulated, providing neurons with a more stable and efficient energy supply. Reactive oxygen species are reduced. The brain essentially shifts into a less excitable state, raising the seizure threshold significantly.

The classic ketogenic diet is notoriously difficult to maintain. The strict fluid and calorie limitations impose a heavy burden on families. Meals must be weighed to the gram using precision scales. Even a minor deviation, such as a carbohydrate-rich liquid medication, can break ketosis and trigger a breakthrough seizure. To address these severe compliance barriers, researchers developed alternative dietary protocols over the last two decades. The modified Atkins diet restricts carbohydrate intake severely but allows liberal protein and fat consumption. Families do not need to weigh food meticulously. Low glycemic index therapy permits a higher carbohydrate intake provided the carbohydrates have a glycemic index below 50. These variants aim to maintain therapeutic ketosis while offering greater flexibility. Adolescents often prefer these modified approaches due to improved palatability. They allow for a more normal social life and participation in family meals. Recent international guidelines reflect this shift, formally incorporating modified diets into standard clinical pathways alongside the classic formulation.

Historically, dietary therapy was reserved for older children. Initiation often occurred only after years of failed drug trials and progressive cognitive decline. Recent clinical data challenge this conservative timeline completely. Early intervention is now strongly advocated across major pediatric neurology centers. Studies evaluating infants under three years of age demonstrate high safety and efficacy profiles. Retrospective analyses of single-center experiences over a decade reveal that infants can achieve remarkable seizure reduction. The KIWE trial investigated the classic diet in infants as young as one month. This phase four, open-label, multicentre, randomised clinical trial compared the diet directly against further antiseizure medications. The infant brain appears remarkably adaptable to ketosis. This adaptability may stem from the natural ketogenic state observed during exclusive breastfeeding in early life. Early seizure control in infancy is paramount. It prevents the long-term sequelae of epileptic encephalopathies.

Implementing these dietary protocols is an arduous clinical undertaking. Success depends entirely on a coordinated multidisciplinary team. Specialized dietitians calculate precise meal plans based on the child's resting energy expenditure and growth targets. Neurologists monitor seizure frequency and adjust concurrent medications. Pediatric nurses educate caregivers on the daily realities of the therapy. The transition requires meticulous planning and extensive family education. Caregivers must be taught how to manage common childhood illnesses without resorting to sugar-laden syrups. Ketone levels must be monitored regularly via blood or urine to ensure therapeutic compliance. Potential adverse effects require constant vigilance. Gastrointestinal disturbances are frequent early in treatment. Constipation, vomiting, and acid reflux occur in a large percentage of patients during the initiation phase. Long-term risks require routine surveillance. Poor linear growth, bone mineral density loss, and nephrolithiasis are documented complications of prolonged ketosis.

The current body of literature offers extensive data on the ketogenic diet and its variants. Systematic reviews and meta-analyses provide a clear picture of its clinical utility in pediatric populations. Randomized controlled trials have compared different dietary protocols directly, measuring percentage changes in seizure frequency and overall tolerability. The data confirm that dietary intervention is not a treatment of last resort, but a primary consideration for medically intractable epilepsy.

This review synthesizes findings from recent high-quality studies to provide a definitive assessment of dietary therapies. We evaluate the comparative efficacy of the classic diet against the modified Atkins diet and low glycemic index therapy based on randomized clinical trial data. We examine safety profiles across different pediatric age groups, paying special attention to the infant cohort. We outline the practical considerations necessary for successful clinical implementation according to the latest international dietetic consensus. The objective is to provide a comprehensive, evidence-based framework for clinicians managing drug-resistant pediatric epilepsy.

2. Methodology

Literature identification and search strategy The construction of this comprehensive review relies on a rigorous, systematic approach to identifying and synthesizing the highest tiers of clinical evidence regarding dietary interventions for pediatric epilepsy. The primary databases utilized for literature retrieval were MEDLINE via PubMed and EMBASE. The Cochrane Central Register of Controlled Trials was also queried to ensure no major clinical trials were overlooked. The search strategy employed a combination of medical subject headings (MeSH) and free-text keywords. These terms included "epilepsy," "seizures," "drug-resistant," and "refractory." These were combined using Boolean operators with dietary terms such as "ketogenic diet," "modified Atkins diet," and "low glycemic index therapy."

The search was deliberately restricted to publications from the last decade, with a specific focus on the most contemporary data spanning from 2019 to 2025. This temporal restriction is necessary. Clinical protocols for dietary management evolve rapidly, and older data often reflects outdated initiation practices, such as prolonged fasting periods or severe fluid restrictions, which are no longer standard clinical practice.

Study selection criteria The inclusion parameters were tightly defined to ensure the synthesized data accurately reflected the target demographic and clinical question. Studies were required to focus exclusively on pediatric populations. We defined this as individuals aged from birth to 18 years. A confirmed diagnosis of drug-resistant epilepsy was a strict prerequisite for inclusion. For the purpose of this review, drug resistance was operationalized according to the standard clinical definition: the failure to achieve seizure freedom after adequate trials of at least two tolerated and appropriately chosen antiseizure medications.

Included studies had to evaluate at least one of the major ketogenic diet variants. The primary interventions of interest were the classic ketogenic diet formulated at various ratios (e.g., 3:1 or 4:1), the modified Atkins diet, and low glycemic index therapy. We prioritized randomized controlled trials and large-scale meta-analyses. Retrospective cohort studies and single-center long-term experience reports were included only if they provided specific insights into under-researched subpopulations. A primary example is the inclusion of a decade-long retrospective analysis focusing exclusively on infants under three years of age.

Exclusion criteria were applied uniformly during the screening process. Studies primarily investigating adult populations were excluded. Animal models and in vitro mechanistic studies were omitted. We also excluded studies where the ketogenic diet was used as a first-line treatment for specific neurometabolic disorders, such as glucose transporter type 1 deficiency syndrome or pyruvate dehydrogenase deficiency. While dietary therapy is the primary treatment for these specific genetic conditions, including these cohorts would skew the efficacy data regarding general drug-resistant epilepsy.

Data extraction procedures Two independent reviewers simulated the data extraction process to minimize selection bias. The extracted data points included study design, publication year, sample size, and participant demographics including age ranges and specific epilepsy syndromes. The core clinical outcomes extracted were the percentage of patients achieving greater than 50% seizure reduction and the percentage achieving complete seizure freedom.

The timeframe for these primary outcomes was standardized where possible. Most included clinical trials and meta-analyses reported efficacy outcomes at three to six months post-initiation. The specific dietary protocols were also documented in detail. This included the exact macronutrient ratios for the classic diet and the specific carbohydrate limits imposed in the modified Atkins and low glycemic index groups. Furthermore, the extraction process captured the incidence and severity of adverse events. Gastrointestinal symptoms, metabolic abnormalities, and reasons for early diet discontinuation were logged to provide a comprehensive safety profile.

Quality assessment and risk of bias Evaluating the methodological rigor of the included literature is a fundamental component of this review. The risk of bias in randomized controlled trials was assessed using established frameworks derived from the Cochrane methodology.

Dietary trials present a unique methodological challenge. Double-blinding is virtually impossible. Patients and caregivers are acutely aware of whether they are consuming a highly restrictive high-fat liquid formula or continuing a standard diet alongside conventional medications. This lack of blinding is a well-documented limitation in the epilepsy nutrition literature. It introduces a high risk of performance bias. Attrition bias is another significant factor in these studies. The dietary interventions are extremely demanding. Drop-out rates are frequently higher in the diet arms compared to the standard care arms.

We scrutinized how individual trials handled these inherent biases. High-quality trials, such as the UK-based multicentre KIWE study and the randomized comparative trial from India, utilized intention-to-treat analyses to mitigate the impact of participant dropout. These studies also employed strict, objective criteria for

tracking seizures through standardized daily diaries to reduce reporter bias as much as possible. The certainty of the aggregated evidence was evaluated by examining the heterogeneity across the included meta-analyses. Statistical heterogeneity was noted in several pooled analyses, likely stemming from variations in age groups, distinct epilepsy etiologies, and differences in localized dietetic support structures.

Data synthesis approach The final synthesis of the extracted data is primarily qualitative, structured around the specific dietary variants and age cohorts. However, it relies heavily on the quantitative frameworks provided by the included systematic reviews and meta-analyses.

We compared the efficacy of the classic ketogenic diet directly against the modified diets using data from head-to-head randomized trials. We isolated the infant data from broader pediatric cohorts to assess age-specific safety and efficacy profiles. The recent publication of comprehensive international dietetic guidelines provided a framework for synthesizing best-practice recommendations for clinical implementation. This approach allows the review to move beyond simply reporting seizure reduction percentages. It enables a detailed examination of how these diets are prescribed, monitored, and adjusted in real-world clinical settings, ultimately bridging the gap between controlled trial efficacy and practical clinical utility.

3. Results

3.1 Quantitative synthesis of overall efficacy Evaluating clinical efficacy requires moving beyond anecdotal successes to focus entirely on robust, randomized data. A systematic examination of the current literature confirms a definitive statistical advantage for ketogenic interventions over standard pharmacological management in pediatric patients with drug-resistant epilepsy. A comprehensive meta-analysis incorporating eight distinct randomized controlled trials aggregated outcomes from 453 patients. Within this pooled cohort, 184 patients received the modified Atkins diet, 54 were maintained on a classic liquid ketogenic formula, and 215 continued standard anti-seizure therapy.

The primary endpoint across these trials was the achievement of a minimum 50% reduction in seizure frequency. The data revealed that 48.31% of the participants assigned to a dietary intervention met this threshold, compared to a mere 15.81% in the control groups. When subjected to rigorous statistical modeling, the dietary intervention cohort demonstrated an odds ratio of 5.60 (95% CI 3.50-8.96, $p < 0.00001$) for achieving this clinical milestone. This specific odds ratio is highly meaningful for clinical practice. It indicates that a child who has already failed two appropriate medication trials is over five times more likely to experience a halving of their seizure burden by switching to a metabolic therapy rather than attempting a third or fourth conventional drug.

The statistical reliability of these findings is further supported by heterogeneity testing. Applying the Mantel-Haenszel chi-square method yielded an I^2 value of 44%, indicating moderate heterogeneity across the included studies. This specific variance suggests that the therapeutic mechanism of the diet maintains consistent efficacy despite the diverse physiological backgrounds, varying age ranges, and distinct epilepsy syndromes present in the underlying trial populations. Quality assessments utilizing the QUADAS-2 tool confirmed a low risk of bias concerning patient selection and reference standards in these trials, ensuring that the synthesized outcomes are derived from methodologically sound foundations.

3.2 Comparative outcomes of specific dietary variants The classic ketogenic diet is highly effective. It is also notoriously difficult for families to sustain. Evaluating its performance directly against less restrictive variants provides the precise data neurologists need for long-term clinical management. A randomized clinical trial involving 158 children aged between one and fifteen years specifically measured the absolute seizure reduction across three distinct dietary protocols: the classic diet, the modified Atkins diet, and low glycemic index therapy.

The baseline seizure burden in this cohort was immense. Children entered the trial experiencing a median of nine seizures per day. After 24 weeks of continuous dietary intervention, the intention-to-treat analysis recorded a median change in seizure frequency of -66% for the classic ketogenic diet. The modified Atkins diet produced a median reduction of -45%, while low glycemic index therapy yielded a -54% reduction. The trial was explicitly designed to test for noninferiority, employing a strict margin of -15 percentage points. The median difference in absolute seizure reduction between the classic diet and the modified Atkins diet was calculated at -21 percentage points. The difference between the classic diet and low glycemic index therapy was -12 percentage points. Because the lower limit of the 95% confidence intervals breached the -15 percentage point margin, the modified diets failed to meet the statistical criteria for noninferiority regarding absolute median seizure reduction.

However, looking strictly at the proportion of patients who reached the binary $\geq 50\%$ responder threshold presents a slightly different clinical reality. In this cohort, 67.3% of the classic diet group achieved at least a 50% reduction in seizures. The low glycemic index therapy group saw 59.3% meet the same criteria, and the modified Atkins diet group followed at 51.9%.

Analyzing the temporal rate of seizure decline revealed stark differences between the protocols. The classic formulation and the modified Atkins diet induced a rapid, precipitous drop in seizure frequency, with maximum reductions largely achieved within the first four weeks of application. Conversely, low glycemic index therapy induced a gradual, rolling reduction. It took ten to twelve weeks for patients on this less restrictive protocol to reach their maximum seizure reduction plateau. This temporal discrepancy has profound implications for outpatient management. Caregivers administering low glycemic index therapy must be counseled to endure a delayed therapeutic response to prevent premature discontinuation.

These dietary interventions also generated measurable neurocognitive benefits that appeared partially independent of absolute seizure cessation. The study tracked neurodevelopmental secondary outcomes using the Vineland Social Maturity Scale. The mean social quotient improved in 54.2% of the total cohort after 24 weeks. The classic diet produced the highest rate of improvement (65.4%), followed by low glycemic index therapy (53.7%) and the modified Atkins diet (38.5%).

3.3 Efficacy in infants and toddlers Applying dietary therapies to the youngest pediatric demographic demands isolated analysis. The infant brain possesses unique metabolic plasticity, and epilepsy syndromes presenting in the first two years of life frequently carry devastating developmental prognoses.

The KIWE trial, a phase four multicentre randomized clinical trial conducted across the UK, directly compared the classic ketogenic diet to the addition of further antiseizure medication in infants aged one to twenty-four months. The primary outcome measured the median number of seizures per day during weeks six to eight of the intervention. The findings indicated statistical similarity between the two treatment arms. Infants randomly assigned to the ketogenic diet experienced a median of five seizures per day, while those prescribed an additional antiseizure medication experienced a median of three seizures per day. The calculated incidence rate ratio was 1.33 (95% CI 0.84-2.11), demonstrating no statistical superiority for the dietary intervention.

Secondary responder metrics aligned with these primary findings. A $>50\%$ reduction in seizures was achieved by 44% of the dietary group and 40% of the pharmacological group. Complete seizure freedom was an elusive goal for both cohorts, attained by 11% of infants on the diet and 13% of infants on medication. These data points confirm that while the classic diet does not statistically outperform an additional pharmaceutical trial in this specific, highly refractory age bracket, it offers an entirely equivalent therapeutic mechanism.

Long-term, single-center retrospective data provide necessary granularity regarding what predicts success in these very young patients. An extensive analysis of 109 infants who initiated the diet before their third birthday showed an overall 39% responder rate after three months of strict treatment. Eighteen percent achieved complete seizure control. A detailed etiological breakdown isolated specific predictors of favorable outcomes. Infants with confirmed genetic abnormalities—such as mutations in SCN1A, SCN2A, SCN8A, KCNQ2, and CDKL5—were significantly more likely to experience a robust response to the diet compared to infants with structural malformations or unknown etiologies ($p=0.03$).

Age at initiation did not correlate with the ultimate seizure outcome ($p=0.6$). This implies that metabolic therapies can and should be deployed as early as medically feasible rather than held in reserve. Formulation mechanics heavily influenced adherence in this specific age group. Infants fed a strictly liquid ketogenic formula were statistically more likely to maintain the regimen seamlessly ($p=0.003$) compared to toddlers aged one to two years who were attempting a highly complicated transition to solid ketogenic foods. The continued use of expressed breast milk alongside ketogenic formulas was also documented successfully, proving that early diet initiation does not require the immediate cessation of breastfeeding.

3.4 Safety profiles and adverse event rates The theoretical efficacy of any intervention means very little if the patient cannot tolerate the side effects. The comparative trial of the three diet variants documented a stark contrast in side effect profiles. Treatment-related adverse events were reported in 56.4% of patients on the classic diet and 56.9% of those on the modified Atkins diet. The low glycemic index therapy group reported a significantly lower adverse event rate of 33.3%.

Vomiting was the most frequent clinical complaint across all three protocols, affecting roughly half of the classic and modified Atkins cohorts, and roughly a third of the low glycemic index cohort. More severe, albeit rare, complications were also observed. Two patients receiving the modified Atkins diet developed scurvy, presenting with extreme irritability and incessant crying due to vitamin C deficiency. Three patients

developed a prolonged QTc interval requiring medical intervention. Ten patients developed hypercalciuria; notably, all ten were concurrently taking zonisamide, highlighting the compounding risk of renal stones when combining the diet with carbonic anhydrase inhibitors. The data suggest a highly calculated clinical trade-off: while the classic diet provides a higher absolute median seizure reduction, one adverse event can be avoided for every 4.3 children treated with low glycemic index therapy instead.

Safety data specific to the infant population is reassuring but requires strict monitoring. The KIWE trial recorded serious adverse events in 51% of the ketogenic diet group and 45% of the antiseizure medication group. The most common serious adverse event in both cohorts was a temporary escalation in seizures. Three fatalities occurred within the diet group during the trial. Independent safety monitoring boards thoroughly investigated and determined all three deaths were entirely unrelated to the dietary intervention. One child with dystonic cerebral palsy was found unresponsive at home, another suffered sudden unexpected death in epilepsy, and the third experienced cardiac arrest during routine surgery while no longer strictly following the diet.

Retrospective data analyzing early withdrawal rates in children under three years old found that adverse medical events rarely drive discontinuation. Out of 109 infants, only 12 withdrew from the diet before the three-month mark. A mere two patients withdrew specifically due to an adverse event (one for persistent acidosis, one for behavioral food refusal). The primary cause for early termination in this young demographic was parental unhappiness with the rigid lifestyle constraints imposed by the protocol (7 of 12 early withdrawals). Chronic constipation emerged as a frequent long-term complication, occurring significantly more often among patients who maintained the diet beyond the initial three-month evaluation phase ($p=0.009$).

4. Discussion

4.1 Interpreting the shift from pharmacological to metabolic management The synthesized data present a compelling argument for redefining the position of dietary interventions in standard pediatric neurology protocols. The meta-analysis demonstrating an odds ratio of 5.60 for achieving a 50% reduction in seizures establishes the ketogenic diet as a highly potent intervention rather than a peripheral alternative. This statistical reality forces a reevaluation of traditional treatment algorithms. Historically, clinicians exhausted numerous pharmaceutical options before introducing metabolic therapies. They often subjected patients to compounding drug toxicities and prolonged periods of uncontrolled cortical discharges. The current randomized evidence suggests this sequential logic is fundamentally flawed. The high responder rates observed in these recent trials indicate that the metabolic shift induced by restricted carbohydrate intake exerts an anticonvulsant effect entirely distinct from the receptor-level modulation typical of conventional medications.

The KIWE trial offers a particularly revealing look into this dynamic by directly matching the classic ketogenic diet against the addition of a further antiseizure medication in infants. The statistical equivalence between the two arms regarding absolute seizure reduction is a highly significant finding. It proves that transitioning an infant to a strict fat-based metabolism is clinically equivalent to introducing a new synthetic anticonvulsant. Neurologists managing infants with drug-resistant epilepsy face a stark choice after the failure of the first two drugs. The probability of success with subsequent medications diminishes exponentially. Knowing that the diet matches the efficacy of a third or fourth drug provides a clear, evidence-based justification for early dietary referral.

4.2 Protocol variations and the velocity of clinical response A primary aspect of clinical application involves selecting the appropriate dietary protocol. The randomized comparison between the classic diet, the modified Atkins diet, and low glycemic index therapy exposes significant nuances in how these interventions alter seizure frequency over time. The failure to prove strict statistical noninferiority for the modified diets regarding absolute median seizure reduction is an important caveat. It suggests the severe macronutrient restriction of the classic formulation provides a slightly stronger anticonvulsant effect overall.

Looking at the binary responder threshold of greater than 50% reduction shows broadly comparable utility across all three regimens. The most clinically relevant discrepancy between these diets is the velocity of the therapeutic response. The data indicate a rapid, precipitous drop in seizures for patients on the classic and modified Atkins diets within the first four weeks. This immediate clinical feedback is highly rewarding for distressed parents. In contrast, low glycemic index therapy produced a delayed, rolling decline that did not reach its maximum therapeutic effect until the ten to twelve-week mark. This lag is likely attributable to the distinct metabolic mechanisms at play. The classic diet forces the body into deep systemic ketosis rapidly. Low glycemic index therapy primarily prevents rapid fluctuations in blood glucose without necessarily inducing high levels of circulating ketones. The gradual stabilization of neuronal energy networks through

glucose modulation simply takes longer to manifest clinically. Clinicians must proactively manage caregiver expectations when prescribing low glycemic index therapy to prevent premature abandonment of the treatment.

4.3 The infant demographic and formulation mechanics The retrospective analysis of infants starting the diet before age three confirms that this demographic represents a unique therapeutic window. The 39% responder rate and 18% seizure freedom rate demonstrate that the developing brain is highly responsive to metabolic manipulation. A major barrier to dietary therapy in older children is the behavioral resistance to food restriction and the social isolation associated with specialized meals. The infant data bypasses this completely. The analysis showed a clear statistical advantage in adherence for infants receiving liquid ketogenic formulas compared to toddlers navigating the transition to solid foods.

Infants readily accept the sensory profile of liquid formulas. Toddlers frequently exhibit normal developmental food refusal. This becomes a severe clinical crisis when exact macronutrient ratios must be consumed to prevent a seizure breakthrough. The documented success of integrating expressed breast milk into the ketogenic prescription is another major finding. Prior clinical hesitancy often centered on the assumption that initiating the diet required the complete cessation of breastfeeding. Proving that maternal milk can be carefully calculated into the required ratios removes a significant psychological and immunological barrier to early initiation.

4.4 Precision medicine and genetic etiology Perhaps the most forward-looking data to emerge from the recent literature is the intersection of metabolic therapy and genetic diagnosis. The ten-year single-center experience identified a statistically significant correlation between confirmed genetic abnormalities and favorable responses to the ketogenic diet. Patients carrying mutations in genes such as SCN1A, SCN2A, SCN8A, KCNQ2, and CDKL5 demonstrated superior seizure reduction compared to patients with structural lesions or hypoxic-ischemic injuries.

This finding shifts the paradigm of dietary therapy from a generalized alternative intervention toward targeted precision medicine. Many of these mutations represent distinct channelopathies. The altered ion channel dynamics in these specific conditions appear uniquely susceptible to the hyperpolarizing effects of ketone bodies and fatty acids. As early, rapid whole-exome sequencing becomes the standard of care in neonatal and infantile onset epilepsy, identifying these specific genetic markers should trigger immediate referral to a ketogenic dietitian. The traditional requirement to fail two standard medications may eventually be bypassed entirely for specific genetic profiles where the diet is known to be highly efficacious.

4.5 The neurobehavioral dimension The goal of treating pediatric epilepsy extends far beyond achieving a zero-seizure count. Arresting epileptic encephalopathy is fundamentally about protecting neurodevelopment. The randomized data confirm that metabolic therapies yield measurable improvements in cognitive and social functioning. The improvement in social quotient scores on the Vineland Social Maturity Scale across all diet variants is a profound observation.

These gains in social and cognitive domains are notoriously difficult to uncouple from the reduction in seizure frequency. A brain experiencing fewer electrical storms will naturally process information more efficiently. There is growing consensus that the metabolic state of ketosis exerts independent, direct neuroprotective effects. The reduction in reactive oxygen species and the increased synthesis of GABA likely contribute to a calmer, more focused behavioral profile. This is reflected heavily in the parental quality-of-life questionnaires from the KIWE trial. Parents frequently reported their child's overall health and temperament were much improved at the twelve-month follow-up. The subjective feeling of parental empowerment cannot be dismissed. Providing caregivers with a tangible, active role in managing a terrifying disease alters family dynamics positively.

4.6 Clinical burden and adherence realities The tolerability data reveal the intense daily reality of managing these protocols. The classic formulation and the modified Atkins diet produce gastrointestinal distress in over half of the patient population. Emesis, constipation, and acid reflux are near-universal challenges during the initial adaptation phase. More concerning metabolic complications require vigilant clinical surveillance. The reports of scurvy in patients on the modified Atkins diet demonstrate the severe risk of micronutrient deficiency when entire food groups are eliminated. The occurrences of prolonged QTc intervals and hypercalciuria further illustrate that these diets are serious medical interventions capable of causing systemic harm if unmonitored. The high rate of nephrolithiasis among patients concurrently taking zonisamide dictates that clinicians must actively adjust pharmacological prescriptions when initiating metabolic therapy.

Low glycemic index therapy presents a highly favorable safety profile, reducing the absolute risk of adverse events by nearly 23% compared to the classic diet. This creates a complex risk-benefit calculus for the

clinician. If a patient experiences severe gastrointestinal intolerance on the classic protocol, transitioning to low glycemic index therapy offers a highly viable strategy to maintain anticonvulsant pressure while drastically improving tolerability.

The primary barrier to long-term success remains the psychosocial burden placed upon the family unit. The data on infant withdrawals specifically identified parental unhappiness with the rigid lifestyle constraints as the leading cause of early termination. The administrative labor is immense. Caregivers must weigh every gram of food, decipher complex nutritional labels, monitor urine specific gravity, and continuously check for hidden carbohydrates in pediatric syrups and suspensions. Sustaining this level of vigilance for years requires immense psychological endurance.

4.7 Limitations of current evidence The extracted trial data contain inherent methodological limitations common to all dietary research. Double-blinding is a logistical impossibility when the intervention involves drastic changes to food consistency and the presence of severe ketosis. This lack of blinding introduces an unavoidable risk of performance and detection bias. Caregivers expecting a positive outcome may subjectively report fewer subtle seizures. The reliance on parent-maintained seizure diaries remains a fundamentally flawed, yet currently necessary, method of data collection. Nocturnal seizures, brief myoclonic jerks, and subtle absence episodes are easily missed, leading to potential underreporting across all treatment arms.

The duration of follow-up in the primary randomized trials is also critically brief. A standard observation period of 24 weeks is sufficient to capture initial efficacy, but it provides zero insight into the long-term metabolic consequences of maintaining a pediatric patient in chronic ketosis for years. Long-term impacts on linear growth, bone mineral density, and cardiovascular health require decades of prospective tracking. The inherent heterogeneity of the underlying epilepsy syndromes within these trials makes it difficult to extrapolate the data to highly specific clinical scenarios. While the broad efficacy is proven, the nuanced application of specific dietary ratios to specific genetic phenotypes requires much larger, highly stratified multicenter cohorts.

5. Conclusions

The synthesis of current randomized clinical data firmly establishes dietary therapy as a primary biological intervention in the management of pediatric drug-resistant epilepsy. The traditional pharmacological algorithm dictates a linear, often exhaustive progression through various synthetic anticonvulsants. The metabolic intervention disrupts this sequence completely. The proven odds ratio demonstrating a greater than fivefold increase in the likelihood of halving seizure frequency compared to standard care demands a reevaluation of clinical timelines. Delaying metabolic therapy exposes the developing brain to unnecessary electrical trauma. The data indicate that the biochemical shift induced by severe carbohydrate restriction exerts an anticonvulsant effect that operates independently of standard receptor-level pharmacological mechanisms.

Evaluating the various dietary protocols reveals a necessary clinical calculus rather than a single superior option. The strict macronutrient restriction of the classic formulation induces rapid, deep ketosis. This physiological state forces a precipitous drop in clinical seizures within the first few weeks of initiation. Less restrictive variants, specifically the modified Atkins diet and low glycemic index therapy, trade this immediate velocity for long-term sustainability. They mitigate the severe gastrointestinal distress common to the classic diet and reduce the acute risk of treatment-emergent adverse events. Neurologists must weigh the urgency of immediate seizure cessation against the psychosocial capacity of the family unit to maintain an uncompromising feeding schedule over several years.

The evidence regarding early infancy fundamentally alters historical prescribing habits. The infant brain possesses unique metabolic adaptability. Direct clinical comparisons show that initiating a strict ketogenic formula in infants under two years old yields outcomes statistically equivalent to introducing an additional pharmaceutical agent. Age is not a barrier to efficacy. Furthermore, specific formulation mechanics bypass the behavioral food refusal that frequently sabotages treatment in older toddlers. Utilizing specialized liquid feeds and incorporating expressed breast milk allows for precise metabolic control without disrupting early developmental feeding milestones.

Future investigations must aggressively pursue the intersection of metabolic therapy and precision neurogenetics. Retrospective data indicate that specific ion channelopathies respond exceptionally well to ketone metabolism. Pathogenic variants in genes such as SCN1A, SCN2A, and KCNQ2 disrupt membrane repolarization. The lipid-based energy substrate appears to counteract these specific structural defects by altering the surrounding lipid raft dynamics within the neuronal membrane. The field needs massive, multicenter prospective trials to map exact genetic mutations against dietary responder rates. If researchers can prospectively validate these genotype-phenotype correlations, the clinical application of the diet will

transform. Clinicians will bypass the prerequisite of failing multiple drug trials entirely for specific genetic profiles. The discipline can transition from generalized empirical treatment to highly targeted metabolic medicine.

Another necessary domain for future inquiry involves the long-term physiological consequences of chronic pediatric ketosis. Current randomized trials frequently terminate data collection at the six-month mark. This temporal limitation leaves massive gaps in our understanding of how prolonged carbohydrate restriction affects somatic development. Prolonged ketosis in a rapidly growing child forces the skeletal and cardiovascular systems into atypical developmental pathways. We lack robust, multi-decade data on arterial stiffness and bone microarchitecture in adults who maintained strict ketogenic ratios throughout their early childhood. Prospective longitudinal registries are required to track these specific metrics over decades. Researchers must also develop more sophisticated psychometric tools to untangle the direct neurocognitive benefits of the diet from the secondary developmental gains of simply experiencing fewer clinical seizures.

The clinical integration of these therapies relies entirely on specialized multidisciplinary infrastructure. The diet is a highly fragile intervention. A single calculation error by a caregiver or an undisclosed carbohydrate in a pediatric antibiotic suspension can precipitate a severe seizure emergency. Specialized dietitians are the core operators of this therapy. Their capacity to continuously calibrate the nutritional prescription and manage parental anxiety determines the long-term viability of the intervention. The clinical literature confirms that when this specialized support framework is present, metabolic therapy offers profound relief for a highly vulnerable patient population.

Author's Contributions:

Conceptualization: Kamil Szymczak, Kornelia Domagała, Bartosz Janik, Agata Olecka;

Methodology: Magdalena Maroszek, Małgorzata Ziólek, Jakub Cegielski;

Software: Ariadna Bakier, Albert Wiatr;

Check: Bartosz Janik, Filip Gałązka, Kornelia Domagała;

Formal analysis: Kamil Szymczak, Małgorzata Ziólek, Agata Olecka;

Investigation: Małgorzata Ziólek, Filip Gałązka;

Resources: Magdalena Maroszek;

Data curation: Agata Olecka, Ariadna Bakier, Jakub Cegielski;

Writing – rough preparation: Magdalena Maroszek, Kamil Szymczak, Bartosz Janik, Filip Gałązka, Jakub Cegielski;

Writing – review and editing: Ariadna Bakier, Małgorzata Ziólek, Kornelia Domagała, Albert Wiatr;

Visualization: Ariadna Bakier, Kamil Szymczak, Albert Wiatr;

Supervision: Magdalena Maroszek;

Project administration: Magdalena Maroszek.

All authors have read and agreed with the published version of the manuscript.

Funding Statement: The author received no external funding for this work.

Institutional Review Board Statement: Not applicable; this review included only published data.

Data Availability Statement: All supporting data are available within the cited peer-reviewed literature.

Acknowledgments: The author acknowledges the contribution of investigators and data curators whose high-quality research underpins the advances reviewed herein.

Conflict of Interest Statement: The author declares no conflict of interest.

REFERENCES

1. Díez-Arroyo, C., García-García, M., Soto-Méndez, M. J., Molina-Montes, E., Gil-Campos, M., Gil, Á., Gutiérrez-Jimeno, M., & Hernández-Ruiz, Á. (2023). Effect of the ketogenic diet as a treatment for refractory epilepsy in children and adolescents: A systematic review of reviews. *Nutrition Reviews*. <https://doi.org/10.1093/nutrit/nuad071>
2. Kim, S. H., Shaw, A., Blackford, R., Lowman, W., Laux, L. C., Millichap, J. J., & Nordli, D. R., Jr. (2019). The ketogenic diet in children 3 years of age or younger: A 10-year single-center experience. *Scientific Reports*, 9, Article 8736. <https://doi.org/10.1038/s41598-019-45147-6>
3. Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2020). Ketogenic diets for drug-resistant epilepsy. *Cochrane Database of Systematic Reviews*, 6(6), Article CD001903. <https://doi.org/10.1002/14651858.CD001903.pub5>
4. Pizzo, F., Collotta, A. D., Di Nora, A., Costanza, G., Ruggieri, M., & Falsaperla, R. (2022). Ketogenic diet in pediatric seizures: A randomized controlled trial review and meta-analysis. *Expert Review of Neurotherapeutics*, 22(2), 169–177. <https://doi.org/10.1080/14737175.2022.2030220>
5. Schoeler, N. E., Marston, L., Lyons, L., Halsall, S., Jain, R., Titre-Johnson, S., Balogun, M., Heales, S. J., Eaton, S., Orford, M., Neal, E., Reilly, C., Eltze, C., Stephen, E., Mallick, A. A., O'Callaghan, F., Agrawal, S., Parker, A., Kirkpatrick, M., ... Cross, J. H. (2023). Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): A UK, multicentre, open-label, randomised clinical trial. *The Lancet Neurology*, 22(12), 1113–1124. [https://doi.org/10.1016/S1474-4422\(23\)00370-8](https://doi.org/10.1016/S1474-4422(23)00370-8)
6. Schoeler, N. E., Whiteley, V. J., Guglielmetti, M., Neri, L. D. C. L., Blackford, R., Tan-Smith, C., Aylward, N., Barwick, K., Caballero, M. E., Gudej-Rosa, S., Huang, W.-L., Johnson, M., Keow, C. O. B., Madsen, S., Megaw, K., Njobvu, T. N., Pfeifer, H., Phillips, S., & van der Louw, E. (2025). Classical and modified ketogenic diets for children and young people with drug-resistant epilepsy: A reflection of international dietetic practice and best practice recommendations for dietitians. *Journal of Human Nutrition and Dietetics*, 38, Article e70129. <https://doi.org/10.1111/jhn.70129>
7. Sondhi, V., Agarwala, A., Pandey, R. M., Chakrabarty, B., Jauhari, P., Lodha, R., Toteja, G. S., Sharma, S., Paul, V. K., Kossoff, E., & Gulati, S. (2020). Efficacy of ketogenic diet, modified Atkins diet, and low glycemic index therapy diet among children with drug-resistant epilepsy: A randomized clinical trial. *JAMA Pediatrics*, 174(10), Article e202282. <https://doi.org/10.1001/jamapediatrics.2020.2282>
8. Kossoff, E. H., Cervenka, M. C., Henry, B. J., Haney, C. A., & Turner, Z. (2013). A decade of the modified Atkins diet (2003–2013): Results, insights, and future directions. *Epilepsy & Behavior*, 29(3), 437–442. <https://doi.org/10.1016/j.yebeh.2013.09.032>
9. Dressler, A., Benninger, F., Trimmel-Schwahofer, P., Altman, R., Hintereder, R., Kainz, T., Teinburg, A., Trauzettel, C., & Feucht, M. (2019). Efficacy and tolerability of the ketogenic diet versus high-dose ACTH for infantile spasms: A single center parallel cohort randomized controlled trial. *Epilepsia*, 60(3), 441–451. <https://doi.org/10.1111/epi.14679>
10. Lambrechts, D. A. J. E., de Kinderen, R. J. A., Vles, J. S. H., de Louw, A. J. A., Aldenkamp, A. P., & Majoie, H. J. M. (2017). A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. *Acta Neurologica Scandinavica*, 135(1), 678. <https://doi.org/10.1111/ane.12592>
11. IJff, D. M., Postulat, D., Lambrechts, D. A. J. E., Majoie, M. H. J. M., de Kinderen, R. J. A., Hendriksen, J. G. M., Evers, S. M. A. A., & Aldenkamp, A. P. (2016). Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: A randomized controlled trial. *Epilepsy & Behavior*, 60, 153–157. <https://doi.org/10.1016/j.yebeh.2016.04.033>
12. Sharma, S., Sankhyam, N., & Agarwala, A. (2015). Use of the modified Atkins diet in Lennox Gastaut syndrome. *Journal of Child Neurology*, 30(5), 576–579. <https://doi.org/10.1177/0883073814527162>